Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity
about
Human complement component C3: cDNA coding sequence and derived primary structureLocal opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosanTag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancerFunctional properties of membrane cofactor protein of complementInhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranesPlasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes.Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.Genetics and complement in atypical HUS.Complementary recognition of alternative pathway activators by decay-accelerating factor and factor HA double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine.Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement.Electrostatic modeling predicts the activities of orthopoxvirus complement control proteinsRegulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor HAltered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease.Complement depletion accelerates the clearance of immune complexes from the circulation of primates.Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopyLeishmania major-human macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion.Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiencyExpression and localization of proteins of the complement system in human skin.Quantitative Modeling of the Alternative Pathway of the Complement SystemMapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3Epstein-Barr virus regulates activation and processing of the third component of complement.Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2Complement activation: an emerging player in the pathogenesis of cardiovascular diseaseDeficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathiesVitamin D metabolites change the phenotype of monoblastic U937 cells.Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuriaBovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.Human Tamm-Horsfall protein, a renal specific protein, serves as a cofactor in complement 3b degradation.Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
P2860
Q24568206-AD934A51-BFF8-48A0-98F8-F5315099EF08Q27485069-ADDAA175-A846-4752-B9C3-0DF101BDCE3BQ28384476-49CF6C55-C565-4198-B1B3-ED3DF77FAA23Q28610962-AAA31CA8-15C3-4AF6-B1C5-BD7E5194CB66Q28610983-8E3D1FA1-86B4-4309-BFD6-33DCB3E7D405Q30425504-55A51667-CDF9-492E-A104-F040AE0D2A0FQ30449395-5520AE5E-23A0-4CC5-94E9-670810F9C5F0Q33389945-02D4D635-4E3E-49E5-BDD2-15EA95D76A17Q33749851-3D5FF81C-8F6C-409A-8F0B-5641ED4D8C71Q33771461-710730D7-1DC5-4EB5-96B8-AD567E0BE84BQ33825957-C1311188-7A30-4D38-9B05-394817671F32Q34066011-F4FDEC19-8C20-46DF-9413-A24A7B2AD634Q34069057-54C9BDEF-4ED0-4A89-9CEB-C603BE9043FFQ34340063-EE208B62-51BF-440E-988D-B8915420AD47Q34542184-B4983CED-8972-4FB1-9A65-E956C3E17C99Q34558907-70FEF619-99CA-4062-9B74-90824783EBA7Q34615166-DAB3DFB2-08A9-4865-AAD7-3126CD0DFC05Q34617128-C870537C-64DC-484F-BCAD-9EB3C5912CC6Q35164659-92583B65-C511-4CD9-9BB6-33A316821A6AQ35498914-BB509567-3538-4B43-945A-9A83AA34380AQ35552728-CE696B8D-1149-49AD-832A-D4A5FFCB98D3Q35609010-4462DFA4-BE00-44D8-9CC7-1A4797F56C4EQ35975481-A90E3385-9D7F-4EEC-BF84-B05FC0070442Q36230727-70301A41-84DC-4BBA-8A1A-40D98E504558Q36254495-CAB86072-4ECF-4E84-81E7-CDCCE5586CD3Q36348868-077716EB-53A9-4FA5-936B-C6B2ECD90A4BQ36348883-71BC0CF2-CB01-4259-9017-231B1216C6F9Q36349022-BAC57E68-2321-4D6D-97A7-F311D29C2CE1Q36350126-B6E6308E-EFB1-45A5-AB56-52D8F488BABEQ36355255-206081F8-E027-462A-8693-FD1497161C8AQ36963833-4E92DBBD-88D0-4915-8FD0-E5DE14974E83Q37288362-C250A919-ADE7-4F26-B2CC-567BDEED8334Q37348185-14929387-D55C-49BA-AE1A-AB2532DD819DQ37499843-1DBF013C-334F-4648-BCCE-E4D7A5A24698Q37507817-3EF75297-E7C4-476B-8A1A-E09C2BABE4ECQ37552016-250D0A45-298C-4DE8-ADEA-90287FC509C4Q38309807-1566A2C3-0910-4792-9287-C3EA6462B78AQ40975346-99BE9C23-7849-417E-94D0-6D798CB8F147Q41106073-240E0E12-5220-4A6F-81C8-A64E361911D1Q41292337-AD1FB90A-4F30-4CBE-83F7-B327B546EC91
P2860
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity
description
1982 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1982
@ast
im November 1982 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1982/11/01)
@sk
vědecký článek publikovaný v roce 1982
@cs
wetenschappelijk artikel (gepubliceerd op 1982/11/01)
@nl
наукова стаття, опублікована в листопаді 1982
@uk
مقالة علمية (نشرت في نوفمبر 1982)
@ar
name
Generation of three different ...... tor H vs CR1 cofactor activity
@ast
Generation of three different ...... tor H vs CR1 cofactor activity
@en
Generation of three different ...... tor H vs CR1 cofactor activity
@nl
type
label
Generation of three different ...... tor H vs CR1 cofactor activity
@ast
Generation of three different ...... tor H vs CR1 cofactor activity
@en
Generation of three different ...... tor H vs CR1 cofactor activity
@nl
prefLabel
Generation of three different ...... tor H vs CR1 cofactor activity
@ast
Generation of three different ...... tor H vs CR1 cofactor activity
@en
Generation of three different ...... tor H vs CR1 cofactor activity
@nl
P2093
P3181
P1476
Generation of three different ...... tor H vs CR1 cofactor activity
@en
P2093
P304
P3181
P407
P577
1982-11-01T00:00:00Z